Comparison of outcomes. (A) Lack of effect of the CR-transplantation interval on the outcome of ALL patients with low-risk disease (n = 42; 27 > 3 months, red; 15 ≤ 3 months, blue) autografted in CR1. (B) Beneficial effect of a longer CR-transplantation interval on the outcome of ALL patients with intermediate- or high-risk disease (n = 58; 32 > 3 months, red; 26 ≤ 3 months, blue) autografted in CR1 (P = .06). (C) Long-term survival of acute leukemia patients alive and well 2 years after allogeneic (blue) or autologous (red) transplantation in CR1 (P = .89).